Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies
Military Medical Academy of S.M. Kirov, Saint-Petersburg, Russia Recent clinical trials about the cardiovascular safety of empagliflozin and liraglutide demonstrated a convincing lowering effect on mortality from cardiovascular causes among the patients with type 2 diabetes. These findings resulted...
Saved in:
| Main Authors: | Vladimir V. Salukhov, Yurii Sh. Khalimov, Sergey B. Shustov, Dmitriy V. Kadin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2018-08-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/9570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardioprotective measures in patients with cardiovascular risk factors and polymorbidity
by: article Editorial
Published: (2022-10-01) -
SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
by: Vladimir V Salukhov, et al.
Published: (2021-01-01) -
Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
by: Vladimir V. Salukhov, et al.
Published: (2016-12-01) -
Elevated triglyceride-glucose index is a risk factor for cardiovascular events in adults with type 1 diabetes: a cohort study
by: Rosa Oh, et al.
Published: (2025-04-01) -
Cardiovascular Effects of Metformin
by: B. T. Kurmanbekova, et al.
Published: (2022-03-01)